Advertisement

Drug Safety

, Volume 24, Issue 13, pp 991–1015 | Cite as

Treating Epilepsy in the Elderly

Safety Considerations
  • Santiago Arroyo
  • Günter Kramer
Practical Drug Safety

Abstract

The incidence of epilepsy increases with advancing age. Epilepsy in the elderly has different aetiologies from that in younger populations, cerebrovascular disease being the most common condition associated with seizures. Partial seizures are the predominant seizure type in older patients. A diagnosis of epilepsy in the elderly is based mainly on the history and is frequently delayed. In addition, seizure imitators are especially frequent. In many cases ancillary tests for diagnosis may show normal age-related variants, sometimes making results difficult to interpret. Treating epilepsy in the elderly is problematic due to a number of issues that relate to age and comorbidity. The physical changes associated with increasing age frequently lead to changes in the pharmacokinetics of many anticonvulsants. The treatment of epilepsy in the elderly is also complicated by the existence of other diseases that might affect the metabolism or excretion of anticonvulsants and the presence of concomitant medications that might interact with them. Moreover, specific trials of anticonvulsants in the aged population are scarce. General guidelines for treatment include starting at lower doses, slowing the titration schedule, individualising the choice of anticonvulsant to the characteristics of the patient, avoiding anticonvulsants with important cognitive or sedative adverse effects, and where possible, treating with monotherapy.

Keywords

Carbamazepine Valproic Acid Status Epilepticus Gabapentin Lamotrigine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Both Dr Arroyo and Dr Kramer have received travel or research grants, cunsultancy fees or have been on the speakers panels of the major pharmaceutical companies that produce anticonvulsants Novatis, Parke Davis/Pfizer, Desitin, Glaxo-Wellcome (now Glaxo Smith Kline), Aventis/Hoechst Marion Rousell, Jansen-Cilag, Novo Nordisk, Sanofi-Synthelabo and UCB.

References

  1. 1.
    Annegers JF, Hauser WA, Lee R-J, et al. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia 1995; 36: 32–33Google Scholar
  2. 2.
    Loiseau J, Loiseau P, Duché B, et al. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann Neurol 1990; 27: 232–7PubMedCrossRefGoogle Scholar
  3. 3.
    Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453–68PubMedCrossRefGoogle Scholar
  4. 4.
    Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352: 1970–3PubMedCrossRefGoogle Scholar
  5. 5.
    Forsgren L, Bucht G, Eriksson S, et al. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996; 37: 224–9PubMedCrossRefGoogle Scholar
  6. 6.
    Olafsson E, Hauser WA, Ludvigsson P, et al. Incidence of epilepsy in rural Iceland: a population-based study. Epilepsia 1996; 37: 951–5PubMedCrossRefGoogle Scholar
  7. 7.
    Hauser WA, Annegers JF, Kurland AH. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991; 32: 429–45PubMedCrossRefGoogle Scholar
  8. 8.
    de la Court A, Breteler MMB, Meinardi H, et al. Prevalence of epilepsy in the elderly: the Rotterdam study. Epilepsia 1996; 37: 141–7PubMedCrossRefGoogle Scholar
  9. 9.
    Keranen T, Sillanpaa M, Riekkinen PJ. Distribution of seizure types in an epileptic population. Epilepsia 1988; 29: 1–7PubMedCrossRefGoogle Scholar
  10. 10.
    Fisher RS, Webber WR, Lesser RP, et al. High-frequency EEG activity at the start of seizures. J Clin Neurophysiol 1992; 9: 441–8PubMedCrossRefGoogle Scholar
  11. 11.
    Gram L, Alving J, Sagild JC, et al. Juvenile myoclonic epilepsy in unexpected age groups. Epilepsy Res 1988; 2(2): 137–40PubMedCrossRefGoogle Scholar
  12. 12.
    Grunewald RA, Panayiotopoulos CP. Diagnosing juvenile myoclonic epilepsy in an elderly patient. Seizure 1994; 3: 239–41PubMedCrossRefGoogle Scholar
  13. 13.
    Nishiura N, Oiwa T. Epilepsy above 70 years of age — four cases with spike and wave complex. Folia Psychiatr Neurol Jpn 1979; 33(3): 263–8PubMedGoogle Scholar
  14. 14.
    Loiseau J, Crespel A, Picot MC, et al. Idiopathic generalized epilepsy of late onset. Seizure 1998; 7: 485–7PubMedCrossRefGoogle Scholar
  15. 15.
    Li X, Breteler MM, de Bruyne MC, et al. Vascular determinants of epilepsy: the Rotterdam Study. Epilepsia 1997; 38: 1216–20PubMedCrossRefGoogle Scholar
  16. 16.
    Berges S, Moulin T, Berger E, et al. Seizures and epilepsy following strokes: recurrence factors. Eur Neurol 2000; 43: 3–8PubMedCrossRefGoogle Scholar
  17. 17.
    Arboix A, Garcia-Eroles L, Massons JB, et al. Predictive factors of early seizures after acute cerebrovascular disease. Stroke 1997; 28: 1590–4PubMedCrossRefGoogle Scholar
  18. 18.
    Reith J, Jorgensen HS, Nakayama H, et al. Seizures in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke 1997; 28: 1585–9PubMedCrossRefGoogle Scholar
  19. 19.
    Burn J, Dennis M, Bamford J, et al. Epileptic seizures after a first stroke: the Oxfordshire community stroke project. BMJ 1997; 315: 1582–7PubMedCrossRefGoogle Scholar
  20. 20.
    So EL, Annegers JF, Hauser WA, et al. Population-based study of seizure disorders after cerebral infarction. Neurology 1996; 46: 350–5PubMedCrossRefGoogle Scholar
  21. 21.
    Faught E, Peters D, Bartolucci A, et al. Seizures after primary intracerebral hemorrhage. Neurology 1989; 39: 1089–93PubMedCrossRefGoogle Scholar
  22. 22.
    Shinton RA, Gill JS, Zezulka AV, et al. The frequency of epilepsy preceding stroke,case-control study in 230 patients. Lancet 1987; 11–3Google Scholar
  23. 23.
    Hesdorffer DC, Hauser WA, Annegers JF, et al. Severe, uncontrolled hypertension and adult-onset seizures: a case- control study in Rochester, Minnesota. Epilepsia 1996; 37: 736–41PubMedCrossRefGoogle Scholar
  24. 24.
    Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology 1996; 46: 727–30PubMedCrossRefGoogle Scholar
  25. 25.
    Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology 1986; 36: 1226–30PubMedCrossRefGoogle Scholar
  26. 26.
    Lowry JK, Snyder JJ, Lowry PW. Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol 1998; 55: 922–8PubMedCrossRefGoogle Scholar
  27. 27.
    Ng SK, Hauser WA, Brust JC, et al. Alcohol consumption and the risk of new onset seizure. N Engl J Med 1988; 319: 666–73PubMedCrossRefGoogle Scholar
  28. 28.
    Harden CL, Rosenbaum DH, Daras M. Hyperglycemia presenting with occipital seizures. Epilepsia 1991; 32: 215–20PubMedCrossRefGoogle Scholar
  29. 29.
    Askenasy JJ, Streifler M, Carasso R. Moderate nonketotic hyperglycemia — a cause of focal epilepsy. Report of two cases and review of literature. Eur Neurol 1977; 16: 51–61PubMedCrossRefGoogle Scholar
  30. 30.
    Spitz MC, Bainbride JL, Ramsay ER, et al. Observations on the delay in the diagnosis of seizures in the elderly [abstract]. Epilepsia 2000; 41Suppl. 7: 109Google Scholar
  31. 31.
    Drury I, Beydoun A. Pitfalls of EEG interpretation in epilepsy. Neurol Clin 1993; 11: 857–81PubMedGoogle Scholar
  32. 32.
    Santamaria J, Chiappa KH. The EEG of drowsiness in normal adults. J Clin Neurophysiol 1987; 4: 327–82PubMedCrossRefGoogle Scholar
  33. 33.
    Drury I, Beydoun A. Interictal epileptiform activity in elderly patients with epilepsy. Electroencephalogr Clin Neurophysiol 1998; 106: 369–73PubMedCrossRefGoogle Scholar
  34. 34.
    Drury I, Selwa LM, Schuh LA, et al. Value of inpatient diagnostic CCTV-EEG monitoring in the elderly. Epilepsia 1999; 40: 1100–2PubMedCrossRefGoogle Scholar
  35. 35.
    van Donselaar CA, Geerts AT, Schimsheimer RJ. Idiopathic first seizure in adult life: who should be treated? BMJ 1991; 302: 620–3PubMedCrossRefGoogle Scholar
  36. 36.
    Schreiner A, Pohlmann-Eden B, Schwartz A, et al. Epileptic seizures in subcortical vascular encephalopathy. J Neurol Sci 1995; 130: 171–7PubMedCrossRefGoogle Scholar
  37. 37.
    Taveras JM. Nuclear magnetic resonance imaging. AJR Am J Roentgenol 1982; 139(2): 406–7PubMedGoogle Scholar
  38. 38.
    Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998; 50: 735–41PubMedCrossRefGoogle Scholar
  39. 39.
    Coeytaux A, Jallon P, Galobardes B, et al. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000; 55: 693–7PubMedCrossRefGoogle Scholar
  40. 40.
    Rumbach L, Sablot D, Berger E, et al. Status epilepticus in stroke: report on a hospital-based stroke cohort. Neurology 2000; 54: 350–4PubMedCrossRefGoogle Scholar
  41. 41.
    Waterhouse EJ, Vaughan JK, Barnes TY, et al. Synergistic effect of status epilepticus and ischemic brain injury on mortality. Epilepsy Res 1998; 29: 175–83PubMedCrossRefGoogle Scholar
  42. 42.
    Allcock LM, O’Shea D. Diagnostic yield and development of a neurocardiovascular investigation unit for older adults in a district hospital. J Gerontol A Biol SciMed Sci 2000; 55(8): M458–62CrossRefGoogle Scholar
  43. 43.
    Tatum WO, Ross J, Cole AJ. Epileptic pseudodementia. Neurology 1998; 50: 1472–5PubMedCrossRefGoogle Scholar
  44. 44.
    Zucconi M, Ferini-Strambi L. NREM parasomnias: arousal disorders and differentiation from nocturnal frontal lobe epilepsy. Clin Neurophysiol 2000 Sep; 111Suppl. 2: S129–35PubMedCrossRefGoogle Scholar
  45. 45.
    Fakhoury T, Abou-Khalil B, Newman K. Psychogenic seizures in old age: a case report. Epilepsia 1993 Nov-Dec; 34(6): 1049–51PubMedCrossRefGoogle Scholar
  46. 46.
    Ochs HR, Otten H, Greenblatt DJ, et al. Diazepam absorption: effects of age, sex, and Billroth gastrectomy. Dig Dis Sci 1982; 27(3): 225–30PubMedCrossRefGoogle Scholar
  47. 47.
    Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979; 27(1): 20–2PubMedGoogle Scholar
  48. 48.
    Koyama H, Sugioka N, Uno A, et al. Age-related alteration of carbamazepine-serum protein binding in man. J Pharm Pharmacol 1999; 51: 1009–14PubMedCrossRefGoogle Scholar
  49. 49.
    Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15(5): 287–94PubMedCrossRefGoogle Scholar
  50. 50.
    Nolan L, O’Malley K. Prescribing for the elderly. Part I: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 362): 142–9PubMedGoogle Scholar
  51. 51.
    Pryor FM, Ramsay DA, Rowan AJ, et al. Diagnostic, demographic and retention issues in managing seizures in older adults [abstract]. Neurology 2000; 54Suppl. 3: A84–5Google Scholar
  52. 52.
    Geddes JW, Ulas J, Brunner LC, et al. Hippocampal excitatory amino acid receptors in elderly, normal individuals and those with Alzheimer’s disease: non-N-methyl-D-aspartate receptors. Neuroscience 1992; 50: 23–34PubMedCrossRefGoogle Scholar
  53. 53.
    Faught E. Epidemiology and drug treatment of epilepsy in elderly people. Drugs Aging 1999; 15: 255–69PubMedCrossRefGoogle Scholar
  54. 54.
    Macdonald RL, Kelly, KM. Antiepileptic drug mechanisms of action. Epilepsia 1995: 32Suppl. 2; S2–12CrossRefGoogle Scholar
  55. 55.
    Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time-dependent changes — autoinduction of carbamazepine epoxidation. J Clin Pharmacol 1986; 26: 459–62PubMedGoogle Scholar
  56. 56.
    Westenberg HG, van der Kleijn E, Oei TT, et al. Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. Clin Pharmacol Ther 1978; 23: 320–8Google Scholar
  57. 57.
    Hockings N, Pall A, Moody J, et al. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol 1986; 22: 725–8PubMedCrossRefGoogle Scholar
  58. 58.
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–51PubMedCrossRefGoogle Scholar
  59. 59.
    Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiat 1995; 58: 44–50PubMedCrossRefGoogle Scholar
  60. 60.
    Callaghan N, Kenny RA, O’Neill B, et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiat 1985; 48: 639–44PubMedCrossRefGoogle Scholar
  61. 61.
    Richens A, Davidson DL, Cartlidge NE, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiat 1994; 57: 682–7PubMedCrossRefGoogle Scholar
  62. 62.
    Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327: 765–71PubMedCrossRefGoogle Scholar
  63. 63.
    Troupin A, Moretti Ojemman L, Halpern L, et al. Carbamazepine — a double-blind comparison with phenytoin. Neurology 1977; 27: 511–9PubMedCrossRefGoogle Scholar
  64. 64.
    Kalviainen R, Aikia M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arandomized, controlled study. ArchNeurol 1995; 52: 989–96Google Scholar
  65. 65.
    Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70–6PubMedCrossRefGoogle Scholar
  66. 66.
    Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81–7PubMedCrossRefGoogle Scholar
  67. 67.
    Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181–8PubMedCrossRefGoogle Scholar
  68. 68.
    Takayanagi K, Hisauchi I, Watanabe J, et al. Carbamazepine-induced sinus node dysfunction and atrioventricular block in elderly women. Jpn Heart J 1998; 39: 469–79PubMedCrossRefGoogle Scholar
  69. 69.
    Umstead GS, Morales M, McKercher PL. Comparison of total, free, and salivary phenytoin concentrations in geriatric patients. Clin Pharm 1986; 5: 59–62PubMedGoogle Scholar
  70. 70.
    Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982; 31(3): 301–4PubMedCrossRefGoogle Scholar
  71. 71.
    Anderson GD, Pak C, Doane KW, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997; 31: 279–84PubMedGoogle Scholar
  72. 72.
    Reidenberg MM, Odar-Cederlof I, von Bahr C, et al. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 1971; 285(5): 264–7PubMedCrossRefGoogle Scholar
  73. 73.
    Turnbull DM, Howel D, Rawlins MD, et al. Which drug for the adult epileptic patient: phenytoin or valproate? BMJ Clin Res Ed 1985; 290: 815–9CrossRefGoogle Scholar
  74. 74.
    Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double- blind comparison with phenytoin. Epilepsia 1999; 40: 601–7PubMedCrossRefGoogle Scholar
  75. 75.
    Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 1990; 31: 584–91PubMedCrossRefGoogle Scholar
  76. 76.
    Tjellesen L, Gotfredsen A, Borg J, et al. Relationship between local and total body bone mineral in epileptic patients and normal subjects. Clin Physiol 1983; 3: 359–64PubMedCrossRefGoogle Scholar
  77. 77.
    Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. BMJ 1973; 4: 695–701PubMedCrossRefGoogle Scholar
  78. 78.
    Martines C, Gatti G, Sasso E, et al. The disposition of primidone in elderly patients. Br J Clin Pharmacol 1990; 30(4): 607–11PubMedCrossRefGoogle Scholar
  79. 79.
    Bryson SM, Verma N, Scott PJ, et al. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol 1983; 16(1): 104–5PubMedCrossRefGoogle Scholar
  80. 80.
    Duncan JS, Patsalos PN, Shorvon SD. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. Epilepsia 1991; 32: 101–15PubMedCrossRefGoogle Scholar
  81. 81.
    Fleitman JS, Bruni J, Perrin JH, et al. Albumin-binding interactions of sodium valproate. J Clin Pharmacol 1980; 20: 514–7PubMedGoogle Scholar
  82. 82.
    Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141–6PubMedCrossRefGoogle Scholar
  83. 83.
    Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000; 55: 588–91PubMedCrossRefGoogle Scholar
  84. 84.
    Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240–4PubMedGoogle Scholar
  85. 85.
    Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47: 626–35PubMedCrossRefGoogle Scholar
  86. 86.
    Isojarvi JI, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51PubMedCrossRefGoogle Scholar
  87. 87.
    Read CL, Stephen LJ, Stolarek IH, et al. Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study. Seizure 1998; 7: 159–62PubMedGoogle Scholar
  88. 88.
    Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning. Comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996; 53: 1008–16PubMedCrossRefGoogle Scholar
  89. 89.
    Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994; 35: 381–90PubMedCrossRefGoogle Scholar
  90. 90.
    Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 1979; 7Suppl. 1: 51S–7PubMedCrossRefGoogle Scholar
  91. 91.
    Bernus I, Dickinson RG, Hooper WD, et al. Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations. Drugs Aging 1997; 10(4): 278–89PubMedCrossRefGoogle Scholar
  92. 92.
    Greenblatt DJ, Allen MD, Locniskar A, et al. Lorazepam kinetics in the elderly. Clin Pharmacol Ther 1979; 26(1): 103–13PubMedGoogle Scholar
  93. 93.
    Lechin F, Van der Dijs B, Benaim M. Benzodiazepines: tolerability in elderly patients. Psychother Psychosom 1996; 65(4): 171–82PubMedCrossRefGoogle Scholar
  94. 94.
    Foy A, O’Connell D, Henry D, et al. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol A Biol Sci Med Sci 1995; 50(2): M99–106PubMedCrossRefGoogle Scholar
  95. 95.
    Kruse WH. Problems and pitfalls in the use of benzodiazepines in the elderly. Drug Saf 1990; 5(5): 328–44PubMedCrossRefGoogle Scholar
  96. 96.
    Trewin VF, Lawrence CJ, Veitch GB. An investigation of the association of benzodiazepines and other hypnotics with the incidence of falls in the elderly. J Clin Pharm Ther 1992; 17(2): 129–33PubMedCrossRefGoogle Scholar
  97. 97.
    Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018–25PubMedCrossRefGoogle Scholar
  98. 98.
    Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807–12PubMedCrossRefGoogle Scholar
  99. 99.
    Binnie CD, Debets RM, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4: 222–9PubMedCrossRefGoogle Scholar
  100. 100.
    Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457–65PubMedCrossRefGoogle Scholar
  101. 101.
    Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535–41PubMedCrossRefGoogle Scholar
  102. 102.
    Wootton R, Soul-Lawton J, Rolan PE, et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997; 43(1): 23–7PubMedCrossRefGoogle Scholar
  103. 103.
    Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149–55PubMedCrossRefGoogle Scholar
  104. 104.
    Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9PubMedCrossRefGoogle Scholar
  105. 105.
    Giorgi L, Gomez G, O’Neill F, et al. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001; 18(8): 621–30PubMedCrossRefGoogle Scholar
  106. 106.
    Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18: 281–96PubMedCrossRefGoogle Scholar
  107. 107.
    Messenheimer JA, Guberman AH. Rash with lamotrigine: dosing guidelines. Epilepsia 2000; 41(4): 488PubMedCrossRefGoogle Scholar
  108. 108.
    Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33(10): 1037–42PubMedCrossRefGoogle Scholar
  109. 109.
    Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55: 437–60PubMedCrossRefGoogle Scholar
  110. 110.
    Snel S, Jansen JA, Mengel HB, et al. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J Clin Pharmacol 1997; 37: 1015–20PubMedGoogle Scholar
  111. 111.
    Samara EE, Gustavson LE, El Shourbagy T, et al. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998; 39: 868–73PubMedCrossRefGoogle Scholar
  112. 112.
    Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997; 38: 445–51PubMedCrossRefGoogle Scholar
  113. 113.
    So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22: 221–6PubMedCrossRefGoogle Scholar
  114. 114.
    Ben-Menachem E. International experience with tiagabine addon therapy. Epilepsia 1995; 36Suppl. 6: S14–21PubMedCrossRefGoogle Scholar
  115. 115.
    Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995; 36Suppl. 6: S2–6PubMedCrossRefGoogle Scholar
  116. 116.
    Brodie MJ, Bomhof MAM, Kälviäinen R. Double-blind comparison of tiagabine and carbamazepine monotherapy in newly diagnosed epilepsy [abstract]. Epilepsia 1997; 38Suppl. 3: 66Google Scholar
  117. 117.
    Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995; 36Suppl. 6: S10–3PubMedCrossRefGoogle Scholar
  118. 118.
    Leppik IE, Gram L, Deaton R, et al. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999; 33: 235–46PubMedCrossRefGoogle Scholar
  119. 119.
    Balslev T, Uldall P, Buchholt J. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. Eur J Paediatr Neurol 2000; 4: 169–70PubMedCrossRefGoogle Scholar
  120. 120.
    Trinka E, Moroder T, Nagler M, et al. Clinical and EEG findings in complex partial status epilepticus with tiagabine. Seizure 1999; 8: 41–4PubMedCrossRefGoogle Scholar
  121. 121.
    Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996; 5: 153–6PubMedGoogle Scholar
  122. 122.
    Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33–42PubMedCrossRefGoogle Scholar
  123. 123.
    Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41Suppl. 1: S61–5PubMedCrossRefGoogle Scholar
  124. 124.
    Abou-Khalil B. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia 2000; 41Suppl. 1: S72–6PubMedCrossRefGoogle Scholar
  125. 125.
    Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41Suppl. 1: S66–71PubMedCrossRefGoogle Scholar
  126. 126.
    Reife RA, Pledger GW. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997; 38Suppl. 1: S31–3PubMedCrossRefGoogle Scholar
  127. 127.
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52: 321–7PubMedCrossRefGoogle Scholar
  128. 128.
    Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41(9): 1167–78PubMedCrossRefGoogle Scholar
  129. 129.
    Petroff OA, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95–9PubMedCrossRefGoogle Scholar
  130. 130.
    Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409–27PubMedCrossRefGoogle Scholar
  131. 131.
    Muscas GC, Chiroli S, Luceri F, et al. Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. Seizure 2000; 9: 47–50PubMedCrossRefGoogle Scholar
  132. 132.
    Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Neurology 1997; 49: 739–45PubMedCrossRefGoogle Scholar
  133. 133.
    Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997; 49: 746–52PubMedCrossRefGoogle Scholar
  134. 134.
    The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double blind, placebocontrolled, parallel-group study. Neurology 1993; 43: 2292–8Google Scholar
  135. 135.
    Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51: 1282–8PubMedCrossRefGoogle Scholar
  136. 136.
    Marson AG, Kadir ZA, Hutton JL, et al. Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000; (2): CD001415PubMedGoogle Scholar
  137. 137.
    Morris GL. Gabapentin. Epilepsia 1999; 40Suppl. 5: S63–70PubMedCrossRefGoogle Scholar
  138. 138.
    DeToledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997; 19: 394–6PubMedCrossRefGoogle Scholar
  139. 139.
    Martin R, Meador K, Turrentine L, et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 2001; 42(6): 764–71PubMedCrossRefGoogle Scholar
  140. 140.
    McLean MJ, Schmutz M, Wamil AW, et al. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35:Suppl. 3: S5–9PubMedCrossRefGoogle Scholar
  141. 141.
    Isojarvi JI, Pakarinen AJ, Rautio A, et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217–20PubMedCrossRefGoogle Scholar
  142. 142.
    Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35:Suppl. 3: S10–3PubMedCrossRefGoogle Scholar
  143. 143.
    Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35Suppl. 3: S14–9PubMedCrossRefGoogle Scholar
  144. 144.
    May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175–81PubMedCrossRefGoogle Scholar
  145. 145.
    Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996; 29: 156–8PubMedCrossRefGoogle Scholar
  146. 146.
    Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. Psychopharmacology Berl 1994; 116: 115–6PubMedCrossRefGoogle Scholar
  147. 147.
    van Heiningen PN, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410–9PubMedCrossRefGoogle Scholar
  148. 148.
    Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: doubleblind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52: 732–7PubMedCrossRefGoogle Scholar
  149. 149.
    Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebocontrolled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41(12): 1597–607PubMedCrossRefGoogle Scholar
  150. 150.
    Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, doubleblind, clinical trial. Neurology 2000; 54: 2245–51PubMedCrossRefGoogle Scholar
  151. 151.
    Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195–204PubMedCrossRefGoogle Scholar
  152. 152.
    Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451–60PubMedCrossRefGoogle Scholar
  153. 153.
    Shorvon S. Oxcarbazepine: a review. Seizure 2000; 9: 75–9PubMedCrossRefGoogle Scholar
  154. 154.
    Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34: 163–5PubMedCrossRefGoogle Scholar
  155. 155.
    Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35Suppl. 3: S23–5PubMedCrossRefGoogle Scholar
  156. 156.
    Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Seizure. Acta Neurol Scand 2001; 104: 167–70PubMedCrossRefGoogle Scholar
  157. 157.
    Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529–33PubMedCrossRefGoogle Scholar
  158. 158.
    Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998; 29: 109–14PubMedCrossRefGoogle Scholar
  159. 159.
    Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997; 38: 1035–8PubMedCrossRefGoogle Scholar
  160. 160.
    Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998; 38: 166–71PubMedGoogle Scholar
  161. 161.
    Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8(3): 293–6PubMedCrossRefGoogle Scholar
  162. 162.
    Yamashita S, Furuno K, Moriyama M, et al. Effects of various antiepileptic drugs on plasma levels of lamotrigine, a novel antiepileptic, in rats. Pharmacology 1997; 54: 319–27PubMedCrossRefGoogle Scholar
  163. 163.
    Tasaki K, Minami T, Ieiri I, et al. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Brain Dev 1995; 17: 182–5PubMedCrossRefGoogle Scholar
  164. 164.
    Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73PubMedCrossRefGoogle Scholar
  165. 165.
    Wilensky AJ, Friel PN, Ojemann LM, et al. Zonisamide in epilepsy: a pilot study. Epilepsia 1985; 26: 212–20PubMedCrossRefGoogle Scholar
  166. 166.
    Kumagai N, Seki T, Yamawaki H, et al. Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatry Neurol 1991; 45(2): 357–9PubMedGoogle Scholar
  167. 167.
    Seino M, Miyazaki H, Ito T. Zonisamide. Epilepsy Res Suppl 1991; 3: 169–74PubMedGoogle Scholar
  168. 168.
    Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2(2): 99–105PubMedGoogle Scholar
  169. 169.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77–85PubMedCrossRefGoogle Scholar
  170. 170.
    Kasteleijn-Nolst TD, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225–30CrossRefGoogle Scholar
  171. 171.
    Browne TR, Szabo GK, Leppik IE, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000; 40(6): 590–5PubMedCrossRefGoogle Scholar
  172. 172.
    Ben Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41(10): 1276–83PubMedCrossRefGoogle Scholar
  173. 173.
    Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80–7PubMedCrossRefGoogle Scholar
  174. 174.
    Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236–42PubMedCrossRefGoogle Scholar
  175. 175.
    Neyens LG, Alpherts WC, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 411–9CrossRefGoogle Scholar
  176. 176.
    The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29–33Google Scholar
  177. 177.
    Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993; 43: 688–92PubMedCrossRefGoogle Scholar
  178. 178.
    Richens A, Banfield CR, Salfi M, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997; 44: 129–34PubMedCrossRefGoogle Scholar
  179. 179.
    Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265–9PubMedCrossRefGoogle Scholar
  180. 180.
    O’Neil MG, Perdun CS, Wilson MB, et al. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46: 1457–9PubMedCrossRefGoogle Scholar
  181. 181.
    Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995; 45: 456–60PubMedCrossRefGoogle Scholar
  182. 182.
    French J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999; 52(8): 1540–5PubMedCrossRefGoogle Scholar
  183. 183.
    Ben-Menachem E. Vigabatrin. Epilepsia 1995; 36Suppl. 2: S95–104PubMedCrossRefGoogle Scholar
  184. 184.
    Beran RG, Berkovic SF, Buchanan N, et al. A double-blind, placebo-controlled crossover study of vigabatrn 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996; 5: 259–65PubMedCrossRefGoogle Scholar
  185. 185.
    Fejerman N, Cersosimo R, Caraballo R, et al. Vigabatrin as a first-choice drug in the treatment of West syndrome. J Child Neurol 2000; 15: 161–5PubMedCrossRefGoogle Scholar
  186. 186.
    Ben-Menachem E, Persson L, Mumford J. Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. Epilepsy Res 1990; 5: 240–6PubMedCrossRefGoogle Scholar
  187. 187.
    Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987; 37: 184–9PubMedCrossRefGoogle Scholar
  188. 188.
    Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 354: 13–9PubMedCrossRefGoogle Scholar
  189. 189.
    Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614–8PubMedCrossRefGoogle Scholar
  190. 190.
    Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999; 53: 2082–7PubMedCrossRefGoogle Scholar
  191. 191.
    Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53(5): 922–6PubMedCrossRefGoogle Scholar
  192. 192.
    Johnson MA, Krauss GL, Miller NR, et al. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55: 40–5PubMedCrossRefGoogle Scholar
  193. 193.
    Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 1989; 30Suppl. 2: S4–10PubMedCrossRefGoogle Scholar
  194. 194.
    Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792–8PubMedCrossRefGoogle Scholar
  195. 195.
    Bleck TP. Management approaches to prolonged seizures and status epilepticus. Epilepsia 1999; 40Suppl. 1: S59–63PubMedCrossRefGoogle Scholar
  196. 196.
    O’Brien TJ, Cascino GD, So EL, et al. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 1998 Oct; 51(4): 1034–9PubMedCrossRefGoogle Scholar
  197. 197.
    Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996 Jun; 46(6 Suppl. 1): S3–7PubMedCrossRefGoogle Scholar
  198. 198.
    Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology 1996; 46: S17–9PubMedCrossRefGoogle Scholar
  199. 199.
    Pryor FM, Gidal B, Ramsay RE, et al. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001; 42(2): 245–50PubMedCrossRefGoogle Scholar
  200. 200.
    Parent JM, Lowenstein H. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 1994; 44: 1837–40PubMedCrossRefGoogle Scholar
  201. 201.
    Harper KW, Collier PS, Dundee JW, et al. Age and nature of operation influence the pharmacokinetics of midazolam. Br J Anaesth 1985; 57: 866–71PubMedCrossRefGoogle Scholar
  202. 202.
    Smith MT, Heazlewood V, Eadie MJ, et al. Pharmacokinetics of midazolam in the aged. Eur J Clin Pharmacol 1984; 26: 381–8PubMedCrossRefGoogle Scholar
  203. 203.
    Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55: 722–4PubMedCrossRefGoogle Scholar
  204. 204.
    Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999; 35(2): 147–53PubMedCrossRefGoogle Scholar
  205. 205.
    Lühdorf K, Jensen LK, Plesner AM. Epilepsy in the elderly: incidence,social function and disability. Epilepsia; 1986; 27: 135–41PubMedCrossRefGoogle Scholar
  206. 206.
    Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338: 429–34PubMedCrossRefGoogle Scholar
  207. 207.
    Baker GA, Nashef L, van Hout BA. Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality. Epilepsia 1997; 38Suppl. 1: S1–8PubMedCrossRefGoogle Scholar
  208. 208.
    Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. community study. Epilepsia 1996; 37: 148–61PubMedCrossRefGoogle Scholar
  209. 209.
    Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999; 8: 339–42PubMedCrossRefGoogle Scholar
  210. 210.
    Finelli PF, Cardi JK. Seizure as a cause of fracture. Neurology 1989; 39: 858–60PubMedCrossRefGoogle Scholar
  211. 211.
    Ramsay E, Rowan AJ, Pryor FM, et al. Seizures in the older patient: demographics, diagnosis, and treatment [abstract]. Epilepsia 2000; 41Suppl. 7: 172Google Scholar
  212. 212.
    Hauser WA, Rich SS, Annegers JF, et al. Seizure recurrence after a first unprovoked seizure: an extended follow-up. Neurology 1990; 40: 1163–70PubMedCrossRefGoogle Scholar
  213. 213.
    Hart YM, Sander JW, Johnson AL, et al. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990; 336: 1271–4PubMedCrossRefGoogle Scholar
  214. 214.
    Rocca WA, Sharbrough FW, Hauser WA, et al. Risk factors for complex partial seizures: a population-based case-control study. Ann Neurol 1987; 21: 22–31PubMedCrossRefGoogle Scholar
  215. 215.
    First Seizure Trial Group (FIR.S.T.Group). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993; 43: 478–83Google Scholar
  216. 216.
    Lühdorf K, Jensen K. Epilepsy in the elderly: prognosis. Acta Neurol Scand 1986; 74: 409–15PubMedCrossRefGoogle Scholar
  217. 217.
    Elwes RDC, Johnson AL, Shorvon SD, et al. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944–77PubMedCrossRefGoogle Scholar
  218. 218.
    Holt-Seitz A, Wirrell EC, Sundaram MB. Seizures in the elderly: etiology and prognosis. Can J Neurol Sci 1999; 26: 110–4PubMedGoogle Scholar
  219. 219.
    Cameron H, Macphee GJ. Anticonvulsant therapy in the elderly — a need for placebo controlled trials. Epilepsy Res 1995; 21: 149–57PubMedCrossRefGoogle Scholar
  220. 220.
    Johnson J, Pryor FM, Ramsay RE, et al. Clinical trials: recruitment challenges in the elderly [abstract]. Epilepsia 2000; 41Suppl. 7: 109Google Scholar
  221. 221.
    Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41(11): 1364–74PubMedCrossRefGoogle Scholar
  222. 222.
    Krämer G. Special features of individual antiepileptic drugs. In: Krämer G, editor. Epilepsy in the elderly. Stuttgart: Thieme Verlag, 1999: 75–103Google Scholar
  223. 223.
    Cockerell OC, Johnson AL, Sander JW, et al. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38: 31–46PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2001

Authors and Affiliations

  • Santiago Arroyo
    • 1
  • Günter Kramer
    • 2
  1. 1.Epilepsy Unit, Hospital Clínico de BarcelonaBarcelonaSpain
  2. 2.Swiss Epilepsy CenterZürichSwitzerland

Personalised recommendations